Researchers identify second macrophage inhibitory pathway as target for cancer immunotherapy

In a study published in Nature Immunology, researchers at Stanford University and colleagues found blocking major histocompatibility complex class I (MHCI) or leukocyte immunoglobulin-like receptor B1 (LILRB1) promoted phagocytosis of tumor cells, suggesting the

Read the full 345 word article

User Sign In